

Allegato B

Marco Ceccanti Curriculum Vitae

Place: Rome
Date: June 16th, 2025

Part I – General Information

Full Name	Marco Ceccanti
Date of Birth	-
Place of Birth	Rome, Italy
Citizenship	Italian
Permanent Address	-
Mobile Phone Number	-
E-mail	-
Spoken Languages	Italian, English, French

Part II – Education

Type	Year	Institution	Notes (Degree, Experience,...)
University graduation	2011	Sapienza University of Rome	110/110 cum laude
PhD	2021	Sapienza University of Rome	Ottimo
Specialty	2017	Sapienza University of Rome	70/70 cum laude
Excellence course	2011	Sapienza University of Rome	Additional educational activities beyond their degree program, aimed at deepening knowledge and promoting cultural enrichment for students with high average exam grades.

Part III – Appointments

IIIA – Academic Appointments

Start	End	Institution	Position
01-nov-2017	31-oct-2018	Sapienza University of Rome	Research grant
03-june-2019	02-june-2024	Sapienza University of Rome	Temporary researcher (A)

IIIB – Other Appointments

Start	End	Institution	Position
Apr 2021	Sep 2021	Policlinico Umberto I	Physician in emergency medicine department
Sep 2021	Nov 2021	Policlinico Umberto I	Physician in the regional referral Rare Neuromuscular Diseases Center
Nov 2021	Dec 2021	Policlinico Umberto I	Physician in emergency medicine department
Dec 2021	Jan 2022	Policlinico Umberto I	Physician in the regional referral Rare Neuromuscular Diseases Center
Jan 2022	Mar 2022	Policlinico Umberto I	Physician in Neuro-Covid ward
Mar 2022	Jun 2024	Policlinico Umberto I	Physician in the regional referral Rare Neuromuscular Diseases Center
Jun 2023	Jun 2035	MIUR	National scientific abilitation for associate professor
Feb 2025	Ongoing	EMA	Consultant for European Medicine Agency (EMA)
Sep 2017	Feb 2019	CER-001-CLIN-009	Studio TANGO. Phase III, multi-center, randomized, 48 weeks, double-blind, parallel-group, placebo-controlled study to evaluate efficacy and safety of CER-001 on vessel wall area in patients with genetically defined familial primary hypoalphalipoproteinemia and receiving background optimized lipid therapy, with optional open-label safety extension
June 2017	Oct 2018	Biogen	Studio CONVERGENCE: Uno studio randomizzato, in doppio cieco, controllato verso placebo, a gruppi paralleli per valutare l'efficacia e la sicurezza di BIIB074 in soggetti con dolore neuropatico da radicolopatia lombosacrale. Sponsor: Convergence Pharmaceuticals Ltd., a Biogen Company Maia Building Babraham Research Campus, Cambridge CB22 3AT, Regno Unito
Dec 2014	June 2016	Alexion Pharmaceuticals, Inc.	REGAIN: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Eculizumab in Subjects With Refractory Generalized Myasthenia Gravis (gMG)
May 2017	June 2022	Baxalta now part of Shire	A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With

			Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Nov 2018	Dec 2020	Ist. Farmacologico Mario Negri	The effects of RNS60 on ALS biomarkers: Studio sui diversi effetti della molecola RNS60, con spiccata azione antiossidante, nel migliorare gli outcome clinici e i biomarcatori di patologia nella sclerosi laterale amiotrofica
June 2022	Ongoing	Regeneron Pharmaceuticals	R3918-MG: efficacy and safety of Pozelimab and Cemdisiran combination therapy in patients with symptomatic generalized myasthenia gravis
June 2021	July 2023	Apellis Pharmaceuticals	MERIDIAN: A phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of Pegcetacoplan in subjects with amyotrophic lateral sclerosis (ALS)
Apr 2022	Ongoing	PTC Therapeutics	CARDINALS: A phase 2, randomized, double-blind, placebo-controlled, parallel study to assess the efficacy, safety, tolerability, PK, and biomarker effects of PTC857 in adult subjects with amyotrophic lateral sclerosis
Apr 2025	Ongoing	Ist. Farmacologico Mario Negri	ALCALs: Trial on the Biological and Clinical Effects of Acetyl-L-carnitine in ALS (ALCALs). Phase II/III multicenter, randomized, double-blind, placebo-controlled trial on acetyl-L-carnitine (ALCAR) in subjects living with amyotrophic lateral sclerosis (ALS).
June 2019	Oct 2021	UCB Biopharma SRL	A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis

Part IV – Teaching experience

Year	Institution	Lecture/Course
2019-2024	Sapienza University of Rome	“Neurology” teaching in the degree course in nursing
2019-2024	Sapienza University of Rome	“Neurology” teaching in the degree course in Physiotherapy

2019-2024	Sapienza University of Rome	“Neurology” teaching in the degree course in dentistry
2017, 2021, 2023	Sapienza University of Rome	Master in “rare diseases”- rare neuromuscular diseases
2017	Sapienza University of Rome	High formation course in “Disturbi da uso di alcol (DUA) e altre dipendenze”
2015-2016, 2018, 2020, 2023	Sapienza University of Rome	High formation course in “Elettromiografia clinica
2020, 2021, 2022, 2023 and 2024	University of Pisa	Residential course “EEG e potenziali evocati”

Part V - Society memberships, Awards and Honors

Year	Title
2012	Poster award by SINC meeting: Preliminary data on deep repetitive Transcranial Magnetic Stimulation -Dr-TMS- in alcoholics: a new hope in alcohol addiction?
2016	Poster award by SINC meeting: Impact of Riluzole on the effects of paired associative stimulation (PAS) on cortical excitability in ALS patients
2017	“Città dei due fiumi” award by the meeting “VIII giornate rodigine di coloproctologia Research & innovation academic forum” for the oral presentation “Stimolazione magnetica transcranica ripetitiva come terapia della bladder pain syndrome: dati preliminari e possibili applicazioni per il dolore pelvico cronico”

Part VI - Funding Information [grants as PI-principal investigator or I-investigator]

Year	Title	Program	Grant value
2025	Role of cardio-specific miRNA as screening test for asymptomatic carriers of transthyretin- mediated hereditary amyloidosis	Alnylam	5.000
2023	Deconvoluting human ALS muscle environment by Spatial Transcriptomics	AFM Telethon	
2022	Screening dei carrier asintomatici per mutazione del gene della transtiretina	Sapienza Grant	
2020	“Studying acetylcholine receptors and muscle regeneration in ALS to develop prognostic markers and potential therapies hampering disease progression	Sapienza Grant	

2019	CK prognostic factor in fast and slow progressive amyotrophic lateral sclerosis	Sapienza Grant	
2019	Valutazione endoscopica ed elettromiografica integrata dei meccanismi patogenetici alla base della disfagia nei pazienti affetti da patologie neurodegenerative e correlazione dei dati con la salute orale e la funzionalità respiratoria nasale	Sapienza Grant	
2018	Analisi del ruolo del sistema endocannabinoide e delle citochine umorali nella Sclerosi Laterale Amiotrofica. Valutazione delle possibili future implicazioni terapeutiche degli endocannabinoidi-like	Sapienza Grant	

Part VII – Research Activities

Keywords	Brief Description
Neuromuscular diseases	I am strongly interested in rare neuromuscular diseases such as ALS, myasthenia gravis, hereditary neuropathies (including ATTRv amyloidosis), and inherited myopathies. These conditions are often complex and underdiagnosed, resulting in delayed treatment and significant patient burden. My focus is on understanding their molecular basis to identify early biomarkers and therapeutic targets. I value the interdisciplinary nature of this field, which integrates neurology, genetics, and advanced diagnostics. Working on rare diseases offers the chance to contribute meaningfully to both research and patient care.
TTR amyloidosis	
Amyotrophic lateral sclerosis	
Myopathy	
Myasthenia gravis	
Rare neuromuscular diseases	

Part VIII – Summary of Scientific Achievements

Product type	Number	Data Base	Start	End
Papers [international]	66	Scopus	2012	2025
Papers [national]	0	-	-	-
Books [scientific]	1	ISBN: 978-88-95425-16-0	2020	2020
Books [teaching]	1	ISBN: 978-8893853019	2022	2022

Total Impact factor	220,7 (Scopus)
Total Citations	1285 (Scopus)
Average Citations per Product	19,5 (Scopus)
Hirsch (H) index	20 (Scopus)

Normalized H index*	1,54 (Scopus)
---------------------	---------------

*H index divided by the academic seniority.

Part IX– Selected Publications

List of the publications selected for the evaluation. For each publication report title, authors, reference data, journal IF (if applicable), citations, press/media release (if any).

Title	Authors	Reference data	Citations (WoS)	journal IF (WoS)
A Novel Mutation in ABCA1 Gene Causing Tangier Disease in an Italian Family with Uncommon Neurological Presentation	Ceccanti M, Cambieri C, Frasca V, Onesti E, Biasiotta A, Giordano C, Bruno SM, Testino G, Lucarelli M, Arca M, Inghilleri M.	2016	22	3,552
Acute flaccid paralysis by enterovirus D68 infection: first Italian description on adult patient and role of electrophysiology	Ceccanti M, Sbardella E, Letteri F, De Michele M, Falcou A, Romanzi F, Onesti E, Inghilleri M.	2017	1	3,508
Modulation of human corticospinal excitability by paired associative stimulation in patients with amyotrophic lateral sclerosis and effects of Riluzole	Ceccanti M, Onesti E, Rubino A, Cambieri C, Tartaglia G, Miscioscia A, Frasca V, Inghilleri M.	2018	21	6,919
Creatine kinase and progression rate in amyotrophic lateral sclerosis	Ceccanti M, Pozzilli V, Cambieri C, Libonati L, Onesti E, Frasca V, Fiorini I, Petrucci A, Garibaldi M, Palma E, Bendotti C, Fabbrizio P, Trolese MC, Nardo G, Inghilleri M.	2020	28	6,6
Effects of 3,4-diaminopyridine on myasthenia gravis: Preliminary results of an open-label study	Ceccanti M, Libonati L, Ruffolo G, Cifelli P, Moret F, Frasca V, Palma E, Inghilleri M, Cambieri C.	2022	2	5,6
The Silent Period for Small Fiber Sensory Neuropathy Assessment in a Mixed Cohort of Transthyretin-Mediated Amyloidosis	Cambieri C, Libonati L, Moret F, Tartaglia G, Garibaldi M, Chimenti C, Inghilleri M, Ceccanti M.	2022	5	4,7
Effects of Skin Stimulation on Sensory-Motor Networks Excitability: Possible Implications for Physical Training in Amyotrophic Lateral Sclerosis	Ceccanti M, Cambieri C, Libonati L, Tartaglia G, Moret F, Garibaldi M, Inghilleri M.	2022	0	3,4
Genetics screening in an Italian cohort of patients with Amyotrophic Lateral Sclerosis: the importance of early testing and its	Libonati L, Cambieri C, Colavito D, Moret F, D'Andrea E, Del Giudice E, Leon A, Inghilleri M, Ceccanti M.	2023	5	4,8

implication				
Oxidative Stress in Transthyretin-Mediated Amyloidosis: An Exploratory Study	Fiore M, Cambieri C, Libonati L, Moret F, D'Andrea E, Di Certo MG, Passananti C, Gabanella F, Corbi N, Garibaldi M, Chimenti C, Alfarano M, Ferraguti G, Francati S, Inghilleri M, Ceccanti M.	2024	0	6
Emotion recognition in amyotrophic lateral sclerosis in a dynamic environment	Ceccanti M, Libonati L, Moret F, D'Andrea E, Gori MC, Bersani FS, Inghilleri M, Cambieri C.	2024	0	3,7
MiR206 and 423-3p Are Differently Modulated in Fast and Slow-Progressing Amyotrophic Lateral Sclerosis Patients	Musarò A, Dobrowolny G, Cambieri C, Libonati L, Moret F, Casola I, Laurenzi G, Garibaldi M, Inghilleri M, Ceccanti M.	2024	1	3,3
Exploring Cardiac Sympathetic Denervation in Transthyretin-Mediated Hereditary Amyloidosis (ATTRv): Insights from 123I-mIBG Scintigraphy	Feo MS, Cambieri C, Galosi E, Frantellizzi V, Chimenti C, Luigetti M, Sciarrone MA, Graziani F, Leonardi L, Musumeci B, Libonati L, Moret F, D'Andrea E, Di Giulio M, Garibaldi M, Forcina F, Truini A, De Vincentis G, Inghilleri M, Ceccanti M.	2025	0	3,0

Rome, June 16th 2025

Marco Ceccanti

marco.ceccanti@uniroma1.it